Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans

Tsuchihashi,Kenji; Kusaba,Hitoshi; Yamada,Yuichi; Okumura,Yuta; Shimokawa,Hozumi; Komoda,Masato; Uchino,Keita; Yoshihiro,Tomoyasu; Tsuruta,Nobuhiro; Hanamura,Fumiyasu; Inadomi,Kyoko; Ito,Mamoru; Sagara,Kosuke; Nakano,Michitaka; Nio,Kenta; Arita,Shuji; Ariyama,Hiroshi; Kohashi,Kenichi; Tominaga,Ryuji; Oda,Yoshinao; Akashi,Koichi; Baba,Eishi

doi:10.3892/mco.2017.1197

May-2017 Volume 6 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2017 Volume 6 Issue 5

Full Size Image

Article Open Access

Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans

Authors:
- Kenji Tsuchihashi
- Hitoshi Kusaba
- Yuichi Yamada
- Yuta Okumura
- Hozumi Shimokawa
- Masato Komoda
- Keita Uchino
- Tomoyasu Yoshihiro
- Nobuhiro Tsuruta
- Fumiyasu Hanamura
- Kyoko Inadomi
- Mamoru Ito
- Kosuke Sagara
- Michitaka Nakano
- Kenta Nio
- Shuji Arita
- Hiroshi Ariyama
- Kenichi Kohashi
- Ryuji Tominaga
- Yoshinao Oda
- Koichi Akashi
- Eishi Baba
View Affiliations / Copyright

Affiliations: Department of Medicine and Biosystemic Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan, Department of Anatomic Pathology and Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan, Department of Oncology, Kyushu National Medical Center, Fukuoka 810-8563, Japan, Department of Gastrointestinal and Medical Oncology, Kyushu Hospital Organization Kyushu Cancer Center, Fukuoka 811‑1395, Japan, Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan, Department of Cardiovascular Surgery, Fukuoka Wajiro Hospital, Fukuoka 811-0213, Japan

Copyright: © Tsuchihashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 665-668
|
Published online on: March 17, 2017

https://doi.org/10.3892/mco.2017.1197
Expand metrics +

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a locally invading tumor, characterized by the presence of the collagen type I α 1 (COL1A1)-platelet-derived growth factor (PDGF) β fusion gene. We herein report the case of a 31-year-old man with a history of resection of an abdominal wall DFSP. The patient presented with chest pain and a computed tomography scan revealed a large mass in the posterior mediastinum and another mass in the right lung. The mediastinal mass was a sarcomatous lesion expressing the COL1A1-PDGFβ fusion gene, suggesting that it represented a metastasis of the DFSP following fibrosarcomatous (FS) transformation. Following resection of the mediastinal metastasis and subsequent radiotherapy, the mass in the right lung was also resected. Due to the emergence of pleural and pancreatic tail metastases, the patient was treated with a combination therapy of adriamycin and ifosfamide. After five courses, the disease progressed and the patient was subsequently treated with pazopanib for ~2 months until further progression. Three years after the diagnosis of the mediastinal metastasis of DFSP, the patient was referred to another hospital for palliative care. The expression of programmed cell death 1 ligand (PD-L1) in the primary and metastatic tumors was investigated: PD-L1 expression was detected in the metastasis but not in the primary tumor. Given that the metastatic tumor exhibited FS transformation (DFSP-FS), PD‑L1 expression may be induced by FS transformation, contributing to the metastasis through escape from immune surveillance. Further investigation of the PD-L1 pathway in DFSP and DFSP-FS in primary as well as metastatic sites is required to evaluate the clinical efficacy of therapies targeting the PD-L1 signaling cascade.

View Figures

View References

1	Hoesly PM, Lowe GC, Lohse CM, Brewer JD and Lehman JS: Prognostic impact of fibrosarcomatous transformation in dermatofibrosarcoma protuberans: A cohort study. J Am Acad Dermatol. 72:419–425. 2015. View Article : Google Scholar : PubMed/NCBI
2	Shimizu A, O'Brien KP, Sjöblom T, Pietras K, Buchdunger E, Collins VP, Heldin CH, Dumanski JP and Ostman A: The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 59:3719–3723. 1999.PubMed/NCBI
3	Liang CA, Jambusaria-Pahlajani A, Karia PS, Elenitsas R, Zhang PD and Schmults CD: A systematic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. J Am Acad Dermatol. 71:781–786. 2014. View Article : Google Scholar : PubMed/NCBI
4	Llombart B, Monteagudo C, Sanmartín O, López-Guerrero JA, Serra-Guillén C, Poveda A, Jorda E, Fernandez-Serra A, Pellín A, Guillén C, et al: Dermatofibrosarcoma protuberans: A clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J Am Acad Dermatol. 65:564–575. 2011. View Article : Google Scholar : PubMed/NCBI
5	Stacchiotti S, Astolfi A, Gronchi A, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, et al: Evolution of Dermatofibrosarcoma protuberans (DFSP) to DFSP-derived fibrosarcoma (FS-DFSP): An event marked by epithelial mesenchymal transition-like process and 22q loss. Mol Cancer Res. 14:820–829. 2016. View Article : Google Scholar : PubMed/NCBI
6	Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y and Zang X: Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 21:24–33. 2015. View Article : Google Scholar : PubMed/NCBI
7	Rutgers EJ, Kroon BB, Albus-Lutter CE and Gortzak E: Dermatofibrosarcoma protuberans: Treatment and prognosis. Eur J Surg Oncol. 18:241–248. 1992.PubMed/NCBI
8	Cai H, Wang Y, Wu J and Shi Y: Dermatofibrosarcoma protuberans: Clinical diagnoses and treatment results of 260 cases in China. J Surg Oncol. 105:142–148. 2012. View Article : Google Scholar : PubMed/NCBI
9	Yokoyama Y, Murakami Y, Sasaki M, Morifuji M, Hayashidani Y, Kobayashi T, Sudo T and Sueda T: Pancreatic metastasis of dermatofibrosarcoma protuberans. J Gastroenterol. 39:798–800. 2004. View Article : Google Scholar : PubMed/NCBI
10	Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU and Bruckner JD: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 20:3586–3591. 2002. View Article : Google Scholar : PubMed/NCBI
11	Malhotra B and Schuetze SM: Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: A review of clinical trial results. Curr Opin Oncol. 24:419–424. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hamberg P, Verweij J and Sleijfer S: (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 15:539–547. 2010. View Article : Google Scholar : PubMed/NCBI
13	Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, et al: Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. J Invest Dermatol. 8:3282016.
14	Zou W, Wolchok JD and Chen L: PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 8:328rev. 2016. View Article : Google Scholar
15	Chen J, Jiang CC, Jin L and Zhang XD: Regulation of PD-L1: A novel role of pro-survival signalling in cancer. Ann Oncol. 27:409–416. 2016. View Article : Google Scholar : PubMed/NCBI
16	Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al: PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 108:djv3032015. View Article : Google Scholar : PubMed/NCBI
17	Takahira T, Oda Y, Tamiya S, Yamamoto H, Kawaguchi K, Kobayashi C, Oda S, Iwamoto Y and Tsuneyoshi M: Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans. Hum Pathol. 35:240–245. 2004. View Article : Google Scholar : PubMed/NCBI
18	Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, et al: Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol Res. 3:1158–1164. 2015. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles